Marianne Schürmann, Pharmacist, M.Sc. Health Policy, Planning & Financing

  • Pharmaceutical consultant. Expert in Pharmaceutical Supply Management, National & Regional Medicines Policy development and implementation support, access to essential medicines, medicines regulation, financing, budgeting and selection of essential and priority medicines.

  • Marianne has been supporting pharmaceutical systems development for over 15 years. This included short-term assignments such as pharmaceutical sector reviews; evaluation of national pharmaceutical procurement agencies; development of alternative financing mechanisms; design and implementation planning of harmonised supply systems; assessment of medicines regulatory authorities; development of regional regulatory harmonisation options; studies on access to medicines; design and implementation of pharmaceutical market studies; and support to regional networking initiatives and implementation of the Medicines Transparency Alliance (MeTA) pilot project.

  • Previously, Marianne worked as a long-term pharmaceutical consultant for the Ministries of Health in the Gambia and Namibia. Her areas of responsibility included all aspects of medicines supply management in the public sector. During her assignment in Namibia she was Technical Advisor in the Ministry's Pharmacy Division. Her work focussed on the development of the National Medicines Policy and implementation plan, design and implementation of in-service training on the rational use of medicines and supply management, and the establishment of medicines use indicator surveys.

  • Marianne has broad field experience including Botswana, the Caribbean Region, Ethiopia, the Gambia, Kenya, Lesotho, Namibia, Nigeria, Papua New Guinea, Rwanda, South Africa, Tanzania, Uganda, Zambia and Zimbabwe.

Contact info: Marianne.Schuermann@hera.eu

Related Stories

News
hera supports the government of Mongolia in improving access to affordable medicines
hera supports the government of Mongolia in improving access to affordable medicines

The Mongolian Vice Minister of Health, Byambsuren Lamjav, met with a hera team in October to discuss ongoing work on improving access to affordable medicines in public hospitals in Mongolia. hera is providing technical assistance to the new government under an Asian Development Bank cooperative project.

Mid-term review of the EU/ACP/WHO Renewed Partnership for strengthening pharmaceutical systems and improving access to quality medicines in 15 African ACP Countries
Mid-term review of the EU/ACP/WHO Renewed Partnership for strengthening pharmaceutical systems and improving access to quality medicines in 15 African ACP Countries

The “The Renewed EU/ACP/WHO Partnership” (RP) was a four year programme (October 2012 – September 2016) with the overall objective to contribute to the achievement of health-related MDGs and to universal health coverage in African ACP countries by improving the availability, affordability and use of safe, effective and quality assured essential medicines for the treatment of priority acute and non-communicable diseases.

SADC Feasibility Study on Regional Manufacturing of Medicines and Health Commodities
SADC Feasibility Study on Regional Manufacturing of Medicines and Health Commodities

Assess the feasibility of the local production of essential medicines especially those related to the three communicable diseases, namely HIV and AIDS, TB and Malaria as well as the production of health commodities for the three diseases.

Assessing the Impact: BMGF & DFID's Reproductive Health Programmes in Low- and Middle-Income Countries
Assessing the Impact: BMGF & DFID's Reproductive Health Programmes in Low- and Middle-Income Countries

In an effort to promote reproductive health and accessibility to quality-assured reproductive health commodities in low- and middle-income countries, the Bill & Melinda Gates Foundation (BMGF) and the Department for International Development (DFID), now known as the Foreign, Commonwealth & Development Office (FCDO), rolled out two independent, yet complementary, programmes geared towards ensuring hormonal contraceptives become more readily available, of high quality and affordable.